bioRxiv Science⌕ Search

Biology subjects

Taran, K. A.

Publications and source records attributed to Taran, K. A..

2 recordsLinked to original sources

Monitoring the stability of transgene expression in lettuce using the RUBY reporter.

Nearly four decades after the first transgenic lettuce was reported, constructs for stable transgene expression remain limited. Notably, the 35S promoter from the Cauliflower Mosaic Virus (35S), which drives strong expression of transgenes in several plant species, has often shown silencing and instability in lettuce. Other promoter/terminator combinations that are commonly used in plant expression vectors have not been extensively studied in lettuce. In this study, we evaluated three different expression constructs in two different horticultural types of lettuce using the non-invasive RUBY reporter, which allowed for the monitoring of transgene expression throughout the process of regeneration during tissue culture, throughout development of the primary transgenics, and in two subsequent sexual generations. The LsUBI promoter/terminator combination resulted in strong, uniform expression throughout regeneration, during growth of the primary transgenics, and in both subsequent generations. The AtUBI promoter/tRBCS combination showed slightly lower levels of expression and intermediate levels of silencing, while the 35S promoter/tHSP combination showed both initial strong expression and frequent silencing. Therefore, our data show that the LsUBI promoter/terminator combination provides strong, uniform expression that is unlikely to result in silencing and that the AtUBI promoter/tRBCS combination is an additional option for stable expression of transgenes in lettuce, especially if an intermediate expression level is desired.

plant biology↗

In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancer

Ras proteins are functionally dependent on one or more lipid modifications.1,2 The dynamic palmitoylation of N-Ras by DHHC palmitoyl acyltransferases and depalmitoylation by ABHD17 serine hydrolases is essential for the growth of NRAS-mutant acute myeloid leukemia (AML) cells.3-6 Here we show that ABD778, an in vivo-active ABHD17 inhibitor, selectively reduces the growth of NRAS-mutant AML and melanoma cell lines and is synergistic with the MEK inhibitor PD0325901 (PD901; mirdametinib). Mechanistically, ABD778 and PD901 induce deep and durable suppression of mitogen activated protein kinase (MAPK) pathway activation. Co-treatment extended the survival of mice transplanted with NrasG12D AMLs, which acquired by-pass mutations at relapse that conferred drug resistance and restored MAPK activation. ABD778 augmented the anti-leukemia activity of PI3 kinase, pan-Ras tri-complex, and FLT3 inhibitors, and restored gilteritinib sensitivity in a patient-derived xenograft model of FLT3 inhibitor resistance. These studies validate the palmitoylation cycle as a therapeutic target in NRAS-mutant cancers.

cancer biology↗